Liver Injury after Selective Androgen Receptor Modulator Intake: A Case Report and Review of the Literature

Abstract

Liver injury associated with selective androgen receptor modulators (SARMs) is an issue that has not been reported often. We report a case of a previously healthy 24-year-old male, who was referred to our hospital for severe jaundice with intense pruritus. He had previously taken the SARM Enobosarm (also known as Ostarine) for muscle-building purposes. Blood serum levels of total bilirubin exceeded 30 mg/dL with only a slight elevation of liver enzymes. Liver biopsy revealed isolated hepatocellular cholestasis (bland cholestasis) with limited inflammation or necrosis. Supportive treatment was begun in our hospital with molecular adsorbent recirculation system (MARS) albumin dialysis, as well as cholestyramine for pruritus relief. During therapy, bilirubin levels and symptoms regressed, and after five sessions of dialysis, the patient could be released from our clinic in a markedly improved clinical and laboratory condition. However, bilirubin parameters regressed slowly after this, reaching normal levels as late as six months after first intake of the compound. Exome-based genetic testing brought about no pathogenic variants for cholestatic liver disease in our patient. Nevertheless, three common heterozygous polymorphisms associated with an increased risk for intrahepatic cholestasis could be identified. Our case demonstrates that SARMs can cause severe liver injuries not prominently mentioned in safety data sheets. Therefore, these compounds constitute a potential danger to the user’s health. This holds especially true when taking SARMs without supervision by a medical professional, which should consist of a thorough monitoring of liver enzyme and bilirubin levels.

Zusammenfassung

Leberschäden im Zusammenhang mit selektiven Androgenrezeptormodulatoren (SARM) stellen eine wenig erforschte Nebenwirkung dieser Substanzklasse dar. Im Folgenden berichten wir von einem zuvor gesunden 24-jährigen Patienten, der uns zur Therapie bei schwerem Ikterus mit massivem Pruritus überwiesen wurde. Er hatte zuvor den SARM Enobosarm (auch bezeichnet als Ostarine) zu Zwecken des Muskelaufbaus eingenommen. Der Wert des Gesamtbilirubin war bei Aufnahme auf über 30 mg/dL gestiegen, gleichzeitig zeigte sich nur eine minimale Erhöhung der Leberenzyme. Eine Leberbiopsie erbrachte den Befund eines Leberschadens vom cholestatischen Typ im Rahmen einer reinen Cholestase ohne begleitende Entzündung. Unsererseits wurde eine Albumindialyse mit dem Molecular Adsorbent Recirculation System (MARS) sowie eine Cholestyramin-Therapie aufgrund des starken Juckreizes eingeleitet. Darunter kam es zu einer deutlichen Regredienz der Gesamtbilirubinwerte und der klinischen Symptomatik, woraufhin der Patient aus unserer Klinik entlassen wurde. Eine vollständige Normalisierung der Bilirubinwerte trat allerdings erst etwa sechs Monate nach der erstmaligen Einnahme des Präparats ein. Eine exombasierte genetische Untersuchung erbrachte keine Hinweise auf pathogene Varianten in Bezug auf cholestatische Lebererkrankungen. Allerdings konnten in unserem Falle drei häufige heterozygote Polymorphismen identifiziert werden, die das Risiko für eine intrahepatische Cholestase erhöhen. Unsere Kasuistik zeigt, dass die Einnahme dieser Androgenrezeptormodulatoren schwere Leberschädigungen hervorrufen kann. Diese Nebenwirkung wird häufig nicht in Sicherheitsdatenblättern erwähnt, obwohl durchaus schwerwiegende Risiken für die Gesundheit bestehen. Dies ist insbesondere der Fall bei Einnahme ohne eine professionelle medizinische Supervision, welche aus engmaschiger Kontrolle der Leberenzyme und Bilirubin bestehen sollte.

Schlüsselwörter

Ostarine - Leberschaden - DILI - Cholestase - SARM - Enobosarm - anabole Steroide

Keywords

Ostarine - Drug-induced liver injury - DILI - Cholestasis - SARM - Enobosarm - Anabolic androgenic steroids

Publication History

Received: 06 July 2023

Accepted after revision: 18 September 2023

Article published online:
23 October 2023

• References

• 1 Solomon ZJ, Mirabal JR, Mazur DJ. et al. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sexual Medicine Reviews 2019; 7: 84-94 DOI: 10.1016/j.sxmr.2018.09.006.
• 2 Narayanan R, Coss CC, Dalton JT. Development of selective androgen receptor modulators (SARMs). Molecular and Cellular Endocrinology 2018; 465: 134-142 DOI: 10.1016/j.mce.2017.06.013.
• 3 Bhasin S, Jameson JL. Disorders of the Testes and Male Reproductive System. et al. Jameson JL, Fauci AS, Kasper DL. Harrison’s Principles of Internal Medicine. New York; NY: McGraw-Hill Education;: 2018
• 4 Commissioner O of the. FDA In Brief: FDA warns against using SARMs in body-building products. FDA. 2019
• 5 Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discovery Today 2007; 12: 241-248 DOI: 10.1016/j.drudis.2007.01.003.
• 6 Christiansen AR, Lipshultz LI, Hotaling JM. et al. Selective androgen receptor modulators: the future of androgen therapy?. Transl Androl Urol 2020; 9: S135-S148 DOI: 10.21037/tau.2019.11.02.
• 7 Clark RV, Walker AC, Andrews S. et al. Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women: SARM GSK2881078: PK, PD, and safety in healthy men and women. Br J Clin Pharmacol 2017; 83: 2179-2194 DOI: 10.1111/bcp.13316.
• 8 Basaria S, Collins L, Dillon EL. et al. The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men. The Journals of Gerontology: Series A 2013; 68: 87-95 DOI: 10.1093/gerona/gls078.
• 9 Dobs AS, Boccia RV, Croot CC. et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013; 14: 335-345 DOI: 10.1016/S1470-2045(13)70055-X.
• 10 Yuan Y, Lee JS, Yost SE. et al. A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. Oncologist 2021; 26: 99-e217 DOI: 10.1002/onco.13583.
• 11 Mohideen H, Hussain H, Dahiya DS. et al. Selective Androgen Receptor Modulators: An Emerging Liver Toxin. J Clin Transl Hepatol 2023; 11: 188-196 DOI: 10.14218/JCTH.2022.00207.
• 12 Hymel BM, Victor DW, Alvarez L. et al. Mastabol induced acute cholestasis: A case report. World J Hepatol 2013; 5: 133-136 DOI: 10.4254/wjh.v5.i3.133.
• 13 Loscalzo J, Fauci AS, Kasper DL. et al. Chapter 340: Toxic and Drug-Induced HepatitisIn: Harrison’s Principles of Internal Medicine. McGraw Hill; 2022
• 14 Berthelot P. Mechanisms and prediction of drug-induced liver disease. Gut 1973; 14: 332-339
• 15 Rao R. Mechanism of drug induced hepatotoxicity. Indian Journal of Pharmacology 1973; 5: 313
• 16 Flores JE, Chitturi S, Walker S. Drug-Induced Liver Injury by Selective Androgenic Receptor Modulators. Hepatol Commun 2020; 4: 450-452 DOI: 10.1002/hep4.1456.
• 17 Barbara M, Dhingra S, Mindikoglu AL. Ligandrol (LGD-4033)-Induced Liver Injury. ACG Case Rep J 2020; 7: e00370 DOI: 10.14309/crj.0000000000000370.
• 18 Barbara M, Dhingra S, Mindikoglu AL. Drug-Induced Liver Injury Associated With Alpha Bolic (RAD-140) and Alpha Elite (RAD-140 and LGD-4033). ACG Case Rep J 2020; 7: e00409 DOI: 10.14309/crj.0000000000000409.
• 19 Bedi H, Hammond C, Sanders D. et al. Drug-Induced Liver Injury From Enobosarm (Ostarine), a Selective Androgen Receptor Modulator. ACG Case Rep J 2021; 8: e00518 DOI: 10.14309/crj.0000000000000518.
• 20 Koller T, Vrbova P, Meciarova I. et al. Liver injury associated with the use of selective androgen receptor modulators and post-cycle therapy: Two case reports and literature review. World J Clin Cases 2021; 9: 4062-4071 DOI: 10.12998/wjcc.v9.i16.4062.
• 21 Kintz P, Gheddar L, Paradis C. et al. Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR- δ) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516 (Cardarine) and MK2866 (Ostarine). Toxics 2021; 9: 251 DOI: 10.3390/toxics9100251.
• 22 Khan S, Fackler J, Gilani A. et al. Selective Androgen Receptor Modulator Induced Hepatotoxicity. Cureus 2022; 14 DOI: 10.7759/cureus.22239.
• 23 Weinblatt D, Roy S. Drug-Induced Liver Injury Secondary to Enobosarm: A Selective Androgen Receptor Modulator. J Med Cases 2022; 13: 244-248 DOI: 10.14740/jmc.v13i5.3937.
• 24 Wallstab F, Jechorek D, Keitel-Anselmino V. et al. Ligandrol-induzierte toxische Hepatopathie – ein Fallbericht. Z Gastroenterol 2023; 61: 522-525 DOI: 10.1055/a-1886-4666.
• 25 Leung K, Yaramada P, Goyal P. et al. RAD-140 Drug-Induced Liver Injury. Ochsner Journal 2022; 22: 361-365 DOI: 10.31486/toj.22.0005.
• 26 Mohamed WT, Jahagirdar V, Fatima I. et al. Selective Androgen Receptor Modulators (SARMs)-Induced Liver Injury: A Case Report and Review of Literature. Cureus 2023; 15: e35094 DOI: 10.7759/cureus.35094.
• 27 El Sherrif Y, Potts JR, Howard MR. et al. Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations?. Liver Int 2013; 33: 1266-1270 DOI: 10.1111/liv.12216.
• 28 Qasim Agha O, Al Hennawi H, Alani M. et al. Anabolic Steroid-Induced Cholestatic Liver Injury: A Case Report. Cureus 2022; 14: e27514 DOI: 10.7759/cureus.27514.
• 29 Chopra S, Gawrieh S, Vuppalanchi R. et al. Role of the Surgical Pathologist in Diagnosis of Drug-induced Liver Injury: Recognizing Specific Patterns of Drug Injury. Adv Anat Pathol 2021; 28: 383-395 DOI: 10.1097/PAP.0000000000000307.
• 30 Abeles RD, Foxton M, Khan S. et al. Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature. BMJ Open Gastroenterol 2020; 7: e000549 DOI: 10.1136/bmjgast-2020-000549.
• 31 Petrovic A, Vukadin S, Sikora R. et al. Anabolic androgenic steroid-induced liver injury: An update. World J Gastroenterol 2022; 28: 3071-3080 DOI: 10.3748/wjg.v28.i26.3071.
• 32 Vitale G, Mattiaccio A, Conti A. et al. Molecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic Cholestasis. Int J Mol Sci 2023; 24: 5823 DOI: 10.3390/ijms24065823.
• 33 Stolz A, Navarro V, Hayashi PH. et al. Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. Aliment Pharmacol Ther 2019; 49: 1195-1204 DOI: 10.1111/apt.15211.
• 34 Jüngst C, Justinger C, Fischer J. et al. Common ABCB4 and ABCB11 Genotypes Are Associated with Idiopathic Chronic Cholestasis in Adults. Dig Dis 2022; 40: 489-496 DOI: 10.1159/000518203.
• 35 Gudbjartsson DF, Helgason H, Gudjonsson SA. et al. Large-scale whole-genome sequencing of the Icelandic population. Nat Genet 2015; 47: 435-444 DOI: 10.1038/ng.3247.
• 36 Dixon PH, van Mil SWC, Chambers J. et al. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 2009; 58: 537-544 DOI: 10.1136/gut.2008.159541.
• 37 Narayanan M, Vora RS, Flynn MM. et al. The Efficacy of Albumin Dialysis in the Treatment of Severe Cholestatic Drug-Induced Liver Injury. Crit Care Explor 2022; 4: e0752 DOI: 10.1097/CCE.0000000000000752.
• 38 Eapen J, Ayoola R, Subramanian RM. „The efficacy of extracorporeal liver support with molecular adsorbent recirculating system in severe drug-induced liver injury“. Oxf Med Case Reports 2018; 2018: omx077 DOI: 10.1093/omcr/omx077.
• 39 Díaz FC, Sáez-González E, Benlloch S. et al. Albumin dialysis with MARS for the treatment of anabolic steroid-induced cholestasis. Ann Hepatol 2016; 15: 939-943 DOI: 10.5604/16652681.1222114.